MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ijd.15628

Медицинская библиотека · International journal of dermatology · 2021

Drug survival and predictor factors for discontinuation of methotrexate in psoriasis: a real-life multicenter study.

Ozkok Akbulut Tugba, Topaloglu Demir Filiz, Oguz Topal Ilteris, Kara Polat Asude, Karadag Ayse Serap, Aslan Kayiran Melek, Ozkur Ezgi, Kıvanc Altunay Ilknur

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Drug survival is useful to evaluate long-term drug performance in daily practice. The aim of this study was to evaluate drug survival for methotrexate (MTX) monotherapy in patients with plaque-type psoriasis.

METHODS

We reviewed 3,512 follow-up charts of patients with psoriasis at five tertiary referral centers between January 2012 and January 2020. We analyzed baseline data and treatment outcomes of patients under MTX monotherapy. Drug survival was analyzed using Kaplan-Meier and Cox regression analyses.

RESULTS

Patients with psoriasis who were treated with MTX monotherapy were enrolled (N = 649). The median duration of drug survival was 15 months (95% CI: 13.2-16.8). The overall drug survival rate was 54.7%, 17.4%, and 8% after 1, 3, and 5 years, respectively. The main reasons for discontinuation were adverse effects (n = 209, 32.2%) and inefficacy (n = 105, 15.6%). Based on multivariate Cox regression analysis, the presence of nausea/vomiting (HR: 2.01, 95% CI: 1.49-2.71; P < 0.001) was observed as a statistically significant risk factor for drug discontinuation. Age over 50 years (HR: 0.68, 95% CI: 0.48-0.97; P = 0.03) and using MTX dose ≥15 mg/weekly were positive predictors for drug survival (HR: 0.72, 95% CI: 0.54-0.95; P = 0.02).

CONCLUSIONS

The average drug survival of MTX was 15 months. MTX is still the first-line treatment of moderate-to-severe plaque psoriasis, as highlighted in guidelines. To prevent premature discontinuation, physicians need to look at the response time of at least 16-24 weeks, especially when a stepwise dose increment is used. The presence of nausea/vomiting seemed to be associated with an approximately twofold risk of discontinuation.

Для цитирования: Ozkok Akbulut Tugba, Topaloglu Demir Filiz, Oguz Topal Ilteris, Kara Polat Asude, Karadag Ayse Serap, Aslan Kayiran Melek, Ozkur Ezgi, Kıvanc Altunay Ilknur. Drug survival and predictor factors for discontinuation of methotrexate in psoriasis: a real-life multicenter study.. International journal of dermatology. 2021. DOI: 10.1111/ijd.15628.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.